These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 24314025)

  • 1. Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies.
    Ebrahimi-Fakhari D; Saidi LJ; Wahlster L
    Acta Neuropathol Commun; 2013 Dec; 1(1):79. PubMed ID: 24314025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular chaperones in Parkinson's disease--present and future.
    Ebrahimi-Fakhari D; Wahlster L; McLean PJ
    J Parkinsons Dis; 2011; 1(4):299-320. PubMed ID: 22279517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular chaperones and co-chaperones in Parkinson disease.
    Dimant H; Ebrahimi-Fakhari D; McLean PJ
    Neuroscientist; 2012 Dec; 18(6):589-601. PubMed ID: 22829394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aggregopathy in neurodegenerative diseases: mechanisms and therapeutic implication.
    Dohm CP; Kermer P; Bähr M
    Neurodegener Dis; 2008; 5(6):321-38. PubMed ID: 18309232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of Parkinson's disease: emerging role of molecular chaperones.
    Bandopadhyay R; de Belleroche J
    Trends Mol Med; 2010 Jan; 16(1):27-36. PubMed ID: 20036196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.
    Kalia SK; Kalia LV; McLean PJ
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):741-53. PubMed ID: 20942788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein degradation pathways in Parkinson's disease: curse or blessing.
    Ebrahimi-Fakhari D; Wahlster L; McLean PJ
    Acta Neuropathol; 2012 Aug; 124(2):153-72. PubMed ID: 22744791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular chaperones and Parkinson's disease.
    Hu S; Tan J; Qin L; Lv L; Yan W; Zhang H; Tang B; Wang C
    Neurobiol Dis; 2021 Dec; 160():105527. PubMed ID: 34626793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsp90 and Its Co-Chaperones in Neurodegenerative Diseases.
    Bohush A; Bieganowski P; Filipek A
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31600883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Chaperone/Co-Chaperone Interactions with Small Molecules: A Novel Approach to Tackle Neurodegenerative Diseases.
    Wang L; Bergkvist L; Kumar R; Winblad B; Pavlov PF
    Cells; 2021 Sep; 10(10):. PubMed ID: 34685574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collective roles of molecular chaperones in protein degradation pathways associated with neurodegenerative diseases.
    Luo GR; Le WD
    Curr Pharm Biotechnol; 2010 Feb; 11(2):180-7. PubMed ID: 20166963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ɑ-Synuclein strains and the variable pathologies of synucleinopathies.
    Peelaerts W; Baekelandt V
    J Neurochem; 2016 Oct; 139 Suppl 1():256-274. PubMed ID: 26924014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of α-Synuclein in Etiology of Neurodegenerative Diseases.
    Krawczuk D; Groblewska M; Mroczko J; Winkel I; Mroczko B
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HSP70-HSP90 Chaperone Networking in Protein-Misfolding Disease.
    Prodromou C; Aran-Guiu X; Oberoi J; Perna L; Chapple JP; van der Spuy J
    Subcell Biochem; 2023; 101():389-425. PubMed ID: 36520314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNAJ Proteins in neurodegeneration: essential and protective factors.
    Zarouchlioti C; Parfitt DA; Li W; Gittings LM; Cheetham ME
    Philos Trans R Soc Lond B Biol Sci; 2018 Jan; 373(1738):. PubMed ID: 29203718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stable alpha-synuclein oligomers strongly inhibit chaperone activity of the Hsp70 system by weak interactions with J-domain co-chaperones.
    Hinault MP; Cuendet AF; Mattoo RU; Mensi M; Dietler G; Lashuel HA; Goloubinoff P
    J Biol Chem; 2010 Dec; 285(49):38173-82. PubMed ID: 20847048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the Role of Ubiquitin-Proteasome System in Parkinson's Disease.
    Behl T; Kumar S; Althafar ZM; Sehgal A; Singh S; Sharma N; Badavath VN; Yadav S; Bhatia S; Al-Harrasi A; Almoshari Y; Almikhlafi MA; Bungau S
    Mol Neurobiol; 2022 Jul; 59(7):4257-4273. PubMed ID: 35505049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.
    Sharma SK; Priya S
    Cell Mol Life Sci; 2017 Feb; 74(4):617-629. PubMed ID: 27522545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular chaperones and associated cellular clearance mechanisms against toxic protein conformers in Parkinson's disease.
    Hinault MP; Farina-Henriquez-Cuendet A; Goloubinoff P
    Neurodegener Dis; 2011; 8(6):397-412. PubMed ID: 21411979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.